TSHA - Company ID 0001806310
Taysha Gene Therapies, Inc. trades as TSHA and has a market capitalization of $1.85 B, making it the #2208 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $9.77M, up 17.3% from the prior year and net income of -$109.00M. This page tracks Taysha Gene Therapies, Inc. through 384 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -6635.3% to -1115.3% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Annual report to shareholders | ARS | 2026-04-22 |
| Proxy materials | DEFA14A | 2026-04-22 |
| Proxy statement | DEF 14A | 2026-04-22 |
| Insider trade | 4 | 2026-04-13 |
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Taysha Gene Therapies
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Taysha Gene Therapies
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 | Taysha Gene Therapies
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting | Taysha Gene Therapies
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Taysha Gene Therapies
The largest companies sharing Taysha Gene Therapies, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Taysha Gene Therapies, Inc. (TSHA) has a market capitalization of $1.85 B as of 2026-07-09, ranking #2208 among US-listed companies.
Taysha Gene Therapies, Inc. reported revenue of $9.77M for fiscal year 2025, an increase of 17.3% year over year.
In its latest fiscal year Taysha Gene Therapies, Inc. reported a net loss of $109.00M.